Efficacy and Safety of Avapritinib in Treating Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Phase I/II, Open-Label, Multicenter Study

BACKGROUND: Avapritinib is a type 1 kinase inhibitor designed to potently and selectively inhibit oncogenic KIT/PDGFRA mutants by targeting the kinase active conformation. This multicenter, single-arm, open-label, phase I/II bridging study of NAVIGATOR in Chinese patients evaluated the safety and th...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Zhang, Xinhua, Deng, Yanhong, Wu, Xin, Zheng, Zhichao, Zhou, Yongjian, Cai, Shirong, Zhang, Yanqiao, Zhang, Jun, Tao, Kaixiong, Cui, Yuehong, Cao, Hui, Shen, Kuntang, Yu, Jiren, Zhou, Ye, Ren, Wenxiao, Qu, Chenglin, Zhao, Wanqi, Hu, Jin, Wang, Wei, Yang, Jason, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907038/
https://www.ncbi.nlm.nih.gov/pubmed/36477870
http://dx.doi.org/10.1093/oncolo/oyac242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907038/
https://www.ncbi.nlm.nih.gov/pubmed/36477870
http://dx.doi.org/10.1093/oncolo/oyac242

Ejemplares similares